Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 3Phase 1 3Phase 4 2Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Dermatologic 3Tumor-Agnostic 2Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Melanoma 2Uveal Melanoma 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × relatlimab × Dermatologic × Clear all
NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
36 enrolled
Dermatologic

Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TriSalus Life Sciences, Inc.

Phase 1 Terminated
67 enrolled
Dermatologic

Uveal Melanoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Bristol-Myers Squibb

Phase 1 Terminated
11 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡